Ick Chan Kwon

USPTO Granted Patents = 30 (Patent Applications = 13)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 4.6

ph-index = 5

Forward Citations = 98(Granted Patents)

Company Filing History:

25 out of 2,168

Korea Institute of Science and Technology

K2b Therapeutics, Inc.

patents

4. 1 out of 1,566

Seoul National University

patents

where one patent can have more than one assignee

Years Active: 2000-2024

Loading Chart...

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12139713 - Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell (2024-11-12),

2. 12006502 - Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell (2024-06-11),

3. 11884935 - Method for inducing trans-differentiation of cardiomyocytes based on exosome (2024-01-30),

4. 11618916 - Probe for measuring activity of Caspase-1 and composition for diagnosis of inflammatory diseases containing same (2023-04-04),

5. 11576976 - Method of treating cancer by using siRNA nanocomplexes (2023-02-14),

6. 11246939 - Immunoregulatory protein-siRNA complex having anticancer activity (2022-02-15),

7. 11015197 - Therapeutic agent for treating cancer comprising anti-miRNA-albumin composite (2021-05-25),

8. 10610602 - Tumor cell-specific responsive self-assembling drug nanoconjugate (2020-04-07),

9. 10557156 - Bacterium constitutively producing monophosphoryl lipid A and method of producing monophosphoryl lipid A by using bacterium (2020-02-11),

10. 10500289 - Method of using methylene blue nanoparticle for detecting cancer by bioimaging (2019-12-10),

11. 10335488 - Method for treating cancer by photodynamic therapy (2019-07-02),

12. 10266820 - RNA/DNA nanoparticle for siRNA target-specific delivery and vehicle including the same (2019-04-23),

13. 10213515 - Glycopeptide for contrast agent targeting cancer cells and contrast agent kit containing the same (2019-02-26),

14. 10172879 - Nanocomplexes for co-delivering a drug and siRNA and uses thereof (2019-01-08),

15. 10086075 - Methylene blue nanoparticle for bioimaging and photodynamic therapy and use thereof (2018-10-02),

Title: Ick Chan Kwon: Innovator in Therapeutic Drug Delivery Systems

Introduction

Ick Chan Kwon is a distinguished inventor based in Seoul, South Korea, known for his groundbreaking work in the field of therapeutic drug delivery systems. With a remarkable portfolio of 30 patents, Kwon has made significant contributions to pharmaceutical innovations, particularly focusing on improving the efficacy of active pharmaceutical ingredients.

Latest Patents

Among his latest patents, Kwon has developed therapeutic compounds designed for red blood cell-mediated delivery of an active pharmaceutical ingredient to target cells. This innovative approach allows the compounds to bind to the CD47 protein on the surface of red blood cells and subsequently transfer to target cells, which may include cancer or fibrotic cells. The therapeutic compounds are ultimately internalized by the target cells via endocytosis, demonstrating a novel method for targeted drug delivery.

Career Highlights

Throughout his career, Ick Chan Kwon has collaborated with renowned institutions to advance scientific research and innovation. He has worked at the Korea Institute of Science and Technology, a leading research organization that emphasizes technological development and innovation in various scientific fields. Additionally, he has been associated with D. R. Nano Co., Ltd., where he has further honed his expertise in nanotechnology and therapeutic applications.

Collaborations

Ick Chan Kwon has collaborated with several esteemed colleagues, including Sehoon Kim and Kwangmeyung Kim. These professional relationships have undoubtedly played a vital role in enhancing his research capabilities and patent development, allowing them to collectively push the boundaries of pharmaceutical science.

Conclusion

Ick Chan Kwon's contributions to therapeutic drug delivery represent a significant advancement in the medical and pharmaceutical fields. His innovative patented methods not only highlight his creativity and dedication as an inventor but also showcase the potential for targeted therapies to improve patient outcomes. As Kwon continues his work, the impact of his inventions will likely expand, paving the way for more effective medical treatments.

This text is generated by artificial intelligence and may not be accurate.